Literature DB >> 17113760

Cdk5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats.

Yi Wen1, Shao-Hua Yang, Ran Liu, Evelyn J Perez, Anne Marie Brun-Zinkernagel, Peter Koulen, James W Simpkins.   

Abstract

Although neurofibrillary tangle (NFT) formation is a central event in both familial and sporadic Alzheimer's disease (AD), neither cellular origin nor functional consequence of the NFTs are fully understood. This largely is due to the lack of available in vivo models for neurofibrillary degeneration (NFD). NFTs have only been identified in transgenic mice, bearing a transgene for a rare hereditary neurodegenerative disease, frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP17). Epidemiological evidence suggests a much higher occurrence of dementia in stroke patients. This may represent the underlying cause of the pathogenesis of sporadic AD, which accounts for the majority of AD cases. We examined pathological markers of AD in a rodent stroke model. Here we show that after transient cerebral ischemia, hyperphosphorylated tau accumulates in neurons of the cerebral cortex in the ischemic area, forms filaments similar to those present in human neurodegenerative tauopathies and colocalizes with markers of apoptosis. As a potential underlying mechanism, we were able to determine that transient ischemia induced tau hyperphosphorylation and NFT-like conformations are associated with aberrant activation of cyclin dependent kinase 5 (Cdk5) and can be rescued by delivery of a potent, but non-specific cyclin dependent kinase inhibitor, roscovitine to the brain. Our study further indicates that accumulation of p35 and its calpain-mediated cleavage product, p25 may account for the deregulation of Cdk5 induced by transient ischemia. We conclude that Cdk5 may be the principal protein kinase responsible for tau hyperphosphorylation and may be a hallmark of the tauopathies in this stroke model.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17113760     DOI: 10.1016/j.bbadis.2006.10.011

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  69 in total

Review 1.  Targeting tau protein in Alzheimer's disease.

Authors:  Cheng-Xin Gong; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

Review 2.  The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia.

Authors:  Costantino Iadecola
Journal:  Acta Neuropathol       Date:  2010-07-11       Impact factor: 17.088

3.  Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing.

Authors:  Yi Wen; W Haung Yu; Bryan Maloney; Jason Bailey; Junrong Ma; Isabelle Marié; Thomas Maurin; Lili Wang; Helen Figueroa; Mathieu Herman; Pavan Krishnamurthy; Li Liu; Emmanuel Planel; Lit-Fui Lau; Debomoy K Lahiri; Karen Duff
Journal:  Neuron       Date:  2008-03-13       Impact factor: 17.173

Review 4.  Vascular disease and cognitive impairment.

Authors:  Christiane Reitz; José A Luchsinger; Richard Mayeux
Journal:  Expert Rev Neurother       Date:  2008-08       Impact factor: 4.618

Review 5.  Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers.

Authors:  Christiane Reitz; Richard Mayeux
Journal:  Biochem Pharmacol       Date:  2014-01-04       Impact factor: 5.858

Review 6.  Modern chronic traumatic encephalopathy in retired athletes: what is the evidence?

Authors:  Stella Karantzoulis; Christopher Randolph
Journal:  Neuropsychol Rev       Date:  2013-11-22       Impact factor: 7.444

7.  Sustained (S)-roscovitine delivery promotes neuroprotection associated with functional recovery and decrease in brain edema in a randomized blind focal cerebral ischemia study.

Authors:  Estelle Rousselet; Anne Létondor; Bénédicte Menn; Yann Courbebaisse; Marie-Lise Quillé; Serge Timsit
Journal:  J Cereb Blood Flow Metab       Date:  2017-06-01       Impact factor: 6.200

Review 8.  Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease.

Authors:  C-X Gong; K Iqbal
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

9.  Intracellular mechanisms of N-acylethanolamine-mediated neuroprotection in a rat model of stroke.

Authors:  P Garg; R S Duncan; S Kaja; P Koulen
Journal:  Neuroscience       Date:  2009-12-03       Impact factor: 3.590

Review 10.  Epidemiology of Alzheimer disease.

Authors:  Richard Mayeux; Yaakov Stern
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.